secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-08-21T23:59:59+00:00
Accession:  0001193125-24-203889
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi halts PRECISION1 trial for TSC1/TSC2 cancers; cuts R&D staff 80%, extends cash runway into 2H 2026
--------------------------------------------------------------------------------

- PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.
- FYARRO Q2 2024 sales of $6.2M; company will focus on FYARRO commercial business for PEComa.
- Workforce reductions: 22 employees (32% total) and 80% of R&D staff; non-recurring charges estimated $2.2-2.5M in Q3 2024.
- Cash runway extended into at least 2H 2026; company hired advisory firm for comprehensive strategic review to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/0001193125-24-203889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/d859038d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-203889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer